

Dean J Kereiakes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7701083/publications.pdf>

Version: 2024-02-01

130
papers

17,099
citations

47006

47
h-index

18647

119
g-index

131
all docs

131
docs citations

131
times ranked

12095
citing authors

#	ARTICLE	IF	CITATIONS
1	Estimation of DAPT Study Treatment Effects in Contemporary Clinical Practice: Findings From the EXTEND-DAPT Study. <i>Circulation</i> , 2022, 145, 97-106.	1.6	20
2	The direct and indirect effects of the COVID-19 pandemic on cardiovascular disease throughout the world. <i>European Heart Journal</i> , 2022, 43, 1154-1156.	2.2	11
3	Outcomes of the Novel Supreme Drug-Eluting Stent in Complex Coronary Lesions: A PIONEER III Substudy. , 2022, 1, 100004.		2
4	Sex-Specific Outcomes After Coronary Intravascular Lithotripsy: A Patient-Level Analysis of the Disrupt CAD Studies. , 2022, 1, 100011.		3
5	Intravascular Lithotripsy for Treatment of Severely Calcified Coronary Lesions: 1-Year Results From the Disrupt CAD III Study. , 2022, 1, 100001.		11
6	Individualizing dual antiplatelet therapy (DAPT) duration based on bleeding risk, ischemic risk, or both: An analysis from the DAPT Study. <i>Cardiovascular Revascularization Medicine</i> , 2022, , .	0.8	1
7	Safety and Efficacy of the Supreme Biodegradable Polymer Sirolimus-Eluting Stent in Patients With Diabetes Mellitus. , 2022, 1, 100033.		0
8	Coronary Obstruction After Transcatheter Aortic Valve Replacement: From Risk Prediction to Prevention. , 2022, , 100386.		0
9	Calcific Plaque Modification by Acoustic Shock Waves. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e009354.	3.9	42
10	Primary Results of the EVOLVE Short DAPT Study. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e010144.	3.9	48
11	Novel Supreme Drug-Eluting Stents With Early Synchronized Antiproliferative Drug Delivery to Inhibit Smooth Muscle Cell Proliferation After Drug-Eluting Stents Implantation in Coronary Artery Disease: Results of the PIONEER III Randomized Clinical Trial. <i>Circulation</i> , 2021, 143, 2143-2154.	1.6	16
12	Very late vasomotor responses and gene expression with bioresorbable scaffolds and metallic drug-eluting stents. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 723-732.	1.7	1
13	Application of Auxiliary VerifyNow Point-of-Care Assays to Assess the Pharmacodynamics of RUC-4, a Novel β_2 Receptor Antagonist. <i>TH Open</i> , 2021, 05, e449-e460.	1.4	5
14	Incidence, Predictors, and Outcomes of Patients Discharged Home Versus Other Medical Facility After Transcatheter or Surgical Aortic Valve Replacement. <i>Structural Heart</i> , 2021, 5, 392-400.	0.6	1
15	Safety and Effectiveness of the SVELTE Fixed-Wire and Rapid Exchange Bioresorbable-Polymer Sirolimus-Eluting Coronary Stent Systems for the Treatment of Atherosclerotic Lesions: Results of the OPTIMIZE Randomized Study. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e010609.	3.9	4
16	Intravascular ultrasound predictors of long-term outcomes following ABSORB bioresorbable scaffold implantation: A pooled analysis of the ABSORB III and ABSORB Japan trials. <i>Journal of Cardiology</i> , 2021, 78, 224-229.	1.9	2
17	Optimal dual antiplatelet therapy duration for bioresorbable scaffolds: an individual patient data pooled analysis of the ABSORB trials. <i>EuroIntervention</i> , 2021, 17, e981-e988.	3.2	8
18	Is two better than one? Re-evaluating the surgical approval process for TAVR. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 68-70.	1.7	0

#	ARTICLE	IF	CITATIONS
19	“Back to the Future” for STEMI?. JACC: Case Reports, 2020, 2, 1651-1653.	0.6	9
20	Intravascular Lithotripsy for Treatment of Severely Calcified Coronary Artery Disease. Journal of the American College of Cardiology, 2020, 76, 2635-2646.	2.8	209
21	Percutaneous Interventions for Secondary Mitral Regurgitation. Circulation: Cardiovascular Interventions, 2020, 13, e008998.	3.9	12
22	Intracoronary ALlogeneic heart STem cells to Achieve myocardial Regeneration (ALLSTAR): a randomized, placebo-controlled, double-blinded trial. European Heart Journal, 2020, 41, 3451-3458.	2.2	78
23	First Human Use of RUC-4: A Nonactivating Second-Generation Small-Molecule Platelet Glycoprotein IIb/IIIa (Integrin α IIb β 23) Inhibitor Designed for Subcutaneous Point-of-Care Treatment of ST-Segment Elevation Myocardial Infarction. Journal of the American Heart Association, 2020, 9, e016552.	3.7	21
24	Clinical Implications of Physical Function and Resilience in Patients Undergoing Transcatheter Aortic Valve Replacement. Journal of the American Heart Association, 2020, 9, e017075.	3.7	11
25	Drug-Coated Balloons for In-Stent Restenosis. Journal of the American College of Cardiology, 2020, 76, 1391-1392.	2.8	3
26	Five-Year Outcomes of Transcatheter or Surgical Aortic-Valve Replacement. New England Journal of Medicine, 2020, 382, 799-809.	27.0	520
27	Evaluation of safety and efficacy of coronary intravascular lithotripsy for treatment of severely calcified coronary stenoses: Design and rationale for the Disrupt CAD III trial. American Heart Journal, 2020, 225, 10-18.	2.7	23
28	“Leave Nothing Behind”. JACC: Cardiovascular Interventions, 2020, 13, 2850-2852.	2.9	1
29	BVS Δ vu: the storm before the calm. EuroIntervention, 2020, 16, 623-625.	3.2	0
30	Impact of High Baseline Left Ventricular Filling Pressure on Transcatheter Aortic Valve Replacement Outcomes in Patients with Significant Mitral Annular Calcification. Journal of the American Society of Echocardiography, 2019, 32, 1067-1074.e1.	2.8	3
31	Interruption of Dual Antiplatelet Therapy Within Six Months After Coronary Stents (from the Dual) Tj ETQq1 1 0.784314 rgBT ₄ /Overlo	1.6	4
32	Changes in mechanical dyssynchrony in severe aortic stenosis patients undergoing transcatheter aortic valve replacement. Echocardiography, 2019, 36, 243-248.	0.9	0
33	Anticoagulation After Surgical or Transcatheter Bioprosthetic Aortic Valve Replacement. Journal of the American College of Cardiology, 2019, 74, 1190-1200.	2.8	42
34	Clinical Outcomes Following Implantation of Thin-Strut, Bioabsorbable Polymer-Coated, Everolimus-Eluting SYNERGY Stents. Circulation: Cardiovascular Interventions, 2019, 12, e008152.	3.9	44
35	The OPTIMIZE randomized trial to assess safety and efficacy of the Svelte IDS and RX Sirolimus-eluting coronary stent Systems for the Treatment of atherosclerotic lesions: Trial design and rationale. American Heart Journal, 2019, 216, 82-90.	2.7	3
36	Clinical Outcomes Before and After Complete Everolimus-Eluting Bioresorbable Scaffold Resorption. Circulation, 2019, 140, 1895-1903.	1.6	57

#	ARTICLE	IF	CITATIONS
37	Time-Varying Outcomes With the Absorb Bioresorbable Vascular Scaffold During 5-Year Follow-up. <i>JAMA Cardiology</i> , 2019, 4, 1261.	6.1	71
38	Calcification and extracellular matrix dysregulation in human postmortem and surgical aortic valves. <i>Heart</i> , 2019, 105, 1616-1621.	2.9	33
39	PCSK9 inhibition in patients with and without prior myocardial infarction or ischemic stroke: A pooled analysis of nine randomized-controlled studies of alirocumab. <i>Journal of Clinical Lipidology</i> , 2019, 13, 443-454.	1.5	2
40	Minimizing radiographic contrast administration during coronary angiography using a novel contrast reduction system: A multicenter observational study of the DyeVert [®] , [†] plus contrast reduction system. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 1228-1235.	1.7	28
41	A meta-analysis of reduced leaflet motion for surgical and transcatheter aortic valves: Relationship to cerebrovascular events and valve degeneration. <i>Cardiovascular Revascularization Medicine</i> , 2018, 19, 868-873.	0.8	17
42	Effect of Mechanically Expanded vs Self-Expanding Transcatheter Aortic Valve Replacement on Mortality and Major Adverse Clinical Events in High-Risk Patients With Aortic Stenosis. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 27.	7.4	135
43	Three-Year Outcomes With the Absorb Bioresorbable Scaffold. <i>Circulation</i> , 2018, 137, 464-479.	1.6	152
44	Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial. <i>Lancet, The</i> , 2018, 392, 1530-1540.	13.7	103
45	Stent Thrombosis. , 2018, , 225-247.		1
46	Evolution of the SYNERGY bioresorbable polymer metallic coronary stent. <i>Future Cardiology</i> , 2018, 14, 307-317.	1.2	11
47	Efficacy and safety of alirocumab in patients with or without prior coronary revascularization: Pooled analysis of eight ODYSSEY phase 3 trials. <i>Atherosclerosis</i> , 2018, 277, 211-218.	0.8	10
48	Rationale and design of the EVOLVE Short DAPT Study to assess 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention. <i>American Heart Journal</i> , 2018, 205, 110-117.	2.7	22
49	The TWENTE Trial in Perspective. <i>JAMA Cardiology</i> , 2017, 2, 235.	6.1	23
50	Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy). <i>Circulation</i> , 2017, 135, 1720-1732.	1.6	17
51	Exercise-induced saphenous vein graft spasm prevented by stenting. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 90, 937-944.	1.7	2
52	Efficacy and Safety of the Absorb Everolimus-Eluting Bioresorbable Scaffold for Treatment of Patients With Diabetes Mellitus. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 42-49.	2.9	21
53	Effect of Technique on Outcomes Following Bioresorbable Vascular Scaffold Implantation. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2863-2874.	2.8	125
54	3-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Coronary Scaffolds. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2852-2862.	2.8	202

#	ARTICLE	IF	CITATIONS
55	Lesion Complexity and Outcomes of Extended Dual Antiplatelet Therapy After Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2213-2223.	2.8	99
56	Efficacy and Safety of the Absorb Bioresorbable Vascular Scaffold in Females and Males. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1881-1890.	2.9	11
57	2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy. <i>Lancet, The</i> , 2017, 390, 760-772.	13.7	163
58	Bioresorbable vascular scaffolds for the treatment of coronary artery disease. <i>Coronary Artery Disease</i> , 2017, 28, 77-89.	0.7	8
59	Effect of alirocumab dose increase on LDL lowering and lipid goal attainment in patients with dyslipidemia. <i>Coronary Artery Disease</i> , 2017, 28, 190-197.	0.7	19
60	Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. <i>New England Journal of Medicine</i> , 2016, 374, 1609-1620.	27.0	3,992
61	Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1735.	7.4	759
62	Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis. <i>Lancet, The</i> , 2016, 387, 2218-2225.	13.7	899
63	Early clinical and echocardiographic outcomes after SAPIEN 3 transcatheter aortic valve replacement in inoperable, high-risk and intermediate-risk patients with aortic stenosis. <i>European Heart Journal</i> , 2016, 37, 2252-2262.	2.2	305
64	Diabetes Mellitus and Prevention of Late Myocardial Infarction After Coronary Stenting in the Randomized Dual Antiplatelet Therapy Study. <i>Circulation</i> , 2016, 133, 1772-1782.	1.6	47
65	Impact of Optimal Medical Therapy in the Dual Antiplatelet Therapy Study. <i>Circulation</i> , 2016, 134, 989-998.	1.6	19
66	Bioresorbable Vascular Scaffolds for Coronary Revascularization. <i>Circulation</i> , 2016, 134, 168-182.	1.6	108
67	One-Year Clinical Outcomes With SAPIEN 3 Transcatheter Aortic Valve Replacement in High-Risk and Inoperable Patients With Severe Aortic Stenosis. <i>Circulation</i> , 2016, 134, 130-140.	1.6	172
68	1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis. <i>Lancet, The</i> , 2016, 387, 1277-1289.	13.7	253
69	Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 138-147.	2.9	49
70	Long-term follow-up of the platinum chromium TAXUS element (ION) stent. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 86, 994-1001.	1.7	6
71	Dual Antiplatelet Therapy Duration Following Coronary Stenting —. <i>Journal of the American College of Cardiology</i> , 2015, 65, 787-790.	2.8	10
72	Systemic Pharmacokinetics of Everolimus Eluted From the Absorb Bioresorbable Vascular Scaffold. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2467-2469.	2.8	6

#	ARTICLE	IF	CITATIONS
73	Safety Profile of a Miniaturized Insertable Cardiac Monitor: Results from Two Prospective Trials. PACE - Pacing and Clinical Electrophysiology, 2015, 38, 1464-1469.	1.2	50
74	Effect of Tricuspid Regurgitation and the Right Heart on Survival After Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2015, 8, .	3.9	148
75	Evaluation of a fully bioresorbable vascular scaffold in patients with coronary artery disease: Design of and rationale for the ABSORB III randomized trial. American Heart Journal, 2015, 170, 641-651.e3.	2.7	34
76	A Randomized Evaluation of the SAPIEN XT Transcatheter Heart Valve System in Patients With Aortic Stenosis Who Are Not Candidates for Surgery. JACC: Cardiovascular Interventions, 2015, 8, 1797-1806.	2.9	90
77	Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study. American Heart Journal, 2015, 169, 906-915.e13.	2.7	294
78	Prasugrel Plus Aspirin Beyond 12 Months Is Associated With Improved Outcomes After Taxus Libert Paclitaxel-Eluting Coronary Stent Placement. Circulation, 2015, 131, 62-73.	1.6	60
79	Evaluating the Generalizability of a Large Streamlined Cardiovascular Trial. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 96-102.	2.2	20
80	Efficacy and Safety of a Novel Bioabsorbable Polymer-Coated, Everolimus-Eluting Coronary Stent. Circulation: Cardiovascular Interventions, 2015, 8, .	3.9	222
81	Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia. Annals of Internal Medicine, 2015, 163, 40-51.	3.9	357
82	Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving Dual Antiplatelet Therapy. JACC: Cardiovascular Interventions, 2015, 8, 1552-1562.	2.9	51
83	Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. New England Journal of Medicine, 2015, 373, 1905-1915.	27.0	554
84	The PCSK9 Inhibitors: A Novel Therapeutic Target Enters Clinical Practice. American Health and Drug Benefits, 2015, 8, 483-9.	0.5	16
85	Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials. BMC Cardiovascular Disorders, 2014, 14, 121.	1.7	48
86	Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents. New England Journal of Medicine, 2014, 371, 2155-2166.	27.0	1,645
87	Appropriate Use Criteria to Reduce Underuse and Overuse of Revascularization. Journal of the American College of Cardiology, 2013, 61, 2024.	2.8	5
88	Everolimus-eluting stents in patients undergoing percutaneous coronary intervention: Final 3-year results of the Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions trial. American Heart Journal, 2013, 166, 1035-1042.	2.7	51
89	Complete Revascularization. Journal of the American College of Cardiology, 2013, 62, 1432-1435.	2.8	8
90	In Mildly Symptomatic Patients, Should an Invasive Strategy with Catheterization and Revascularization Be Routinely Undertaken?. Circulation: Cardiovascular Interventions, 2013, 6, 107-113.	3.9	0

#	ARTICLE	IF	CITATIONS
91	Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis. <i>BMJ</i> , The, 2013, 347, f6530-f6530.	6.0	194
92	Periprocedural Myocardial Infarction in a Randomized Trial of Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 150-156.	3.9	40
93	Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study. <i>Cardiovascular Diabetology</i> , 2012, 11, 134.	6.8	29
94	Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy. <i>Journal of the American College of Cardiology</i> , 2012, 59, 2344-2353.	2.8	461
95	Percutaneous Coronary Intervention Use in the United States. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 229-235.	2.9	50
96	Triple-Combination Therapy with Olmesartan, Amlodipine, and Hydrochlorothiazide in Black and Non-Black Study Participants with Hypertension. <i>American Journal of Cardiovascular Drugs</i> , 2012, 12, 233-243.	2.2	22
97	The XIENCE nano [®] , [†] everolimus eluting coronary stent system for the treatment of small coronary arteries: The SPIRIT small vessel trial. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 80, 546-553.	1.7	49
98	Risk Stratification and Timing of Revascularization: Which Patients Benefit from Early Versus Later Revascularization?. <i>Current Cardiology Reports</i> , 2012, 14, 510-520.	2.9	3
99	Long-Term Efficacy and Safety of Triple-Combination Therapy With Olmesartan Medoxomil and Amlodipine Besylate and Hydrochlorothiazide for Hypertension. <i>Journal of Clinical Hypertension</i> , 2012, 14, 149-157.	2.0	19
100	Longitudinal stent deformation: quantitative coronary angiographic analysis from the PERSEUS and PLATINUM randomised controlled clinical trials. <i>EuroIntervention</i> , 2012, 8, 187-195.	3.2	35
101	Stent thrombosis: insights on outcomes, predictors and impact of dual antiplatelet therapy interruption from the SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE trials. <i>EuroIntervention</i> , 2012, 8, 599-606.	3.2	51
102	Randomized Comparison of Everolimus- and Paclitaxel-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2011, 58, 19-25.	2.8	213
103	Seated Cuff Blood Pressure-Lowering Efficacy of an Olmesartan Medoxomil-Based Treatment Regimen in Patients with Type 2 Diabetes Mellitus. <i>Drugs in R and D</i> , 2011, 11, 251-257.	2.2	3
104	Propensity-Matched Patient-Level Comparison of the TAXUS Libert [®] and TAXUS Element (ION) Paclitaxel-Eluting Stents. <i>American Journal of Cardiology</i> , 2011, 108, 828-837.	1.6	15
105	Differential Clinical Responses to Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents in Patients With and Without Diabetes Mellitus. <i>Circulation</i> , 2011, 124, 893-900.	1.6	188
106	A prospective evaluation of the safety and efficacy of TAXUS Element paclitaxel-eluting coronary stent implantation for the treatment of de novo coronary artery lesions in small vessels: the PERSEUS Small Vessel trial. <i>EuroIntervention</i> , 2011, 6, 920-927.	3.2	28
107	Predictors of death or myocardial infarction, ischaemic-driven revascularisation, and major adverse cardiovascular events following everolimus-eluting or paclitaxel-eluting stent deployment: pooled analysis from the SPIRIT II, III, IV and COMPARE trials. <i>EuroIntervention</i> , 2011, 7, 74-83.	3.2	35
108	Comparison of Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents in Patients Undergoing Multilesion and Multivessel Intervention. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 1229-1239.	2.9	42

#	ARTICLE	IF	CITATIONS
109	A prospective evaluation of the safety and efficacy of the TAXUS Element paclitaxel-eluting coronary stent system for the treatment of de novo coronary artery lesions: Design and statistical methods of the PERSEUS clinical program. <i>Trials</i> , 2010, 11, 1.	1.6	56
110	Efficacy of an olmesartan medoxomil-based treatment algorithm in patients with hypertension and type 2 diabetes: analysis of diurnal blood pressure control as assessed by 24-hour ambulatory blood pressure monitoring. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2010, 4, 285-293.	2.1	3
111	Effects of an olmesartan medoxomil based treatment algorithm on 24-hour blood pressure control in patients with hypertension and type 2 diabetes. <i>Current Medical Research and Opinion</i> , 2010, 26, 721-728.	1.9	23
112	Everolimus-Eluting versus Paclitaxel-Eluting Stents in Coronary Artery Disease. <i>New England Journal of Medicine</i> , 2010, 362, 1663-1674.	27.0	812
113	Cultivating Prognosis Following Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2010, 55, 1933-1935.	2.8	5
114	Clinical and Angiographic Outcomes After Treatment of De Novo Coronary Stenoses With a Novel Platinum Chromium Thin-Strut Stent. <i>Journal of the American College of Cardiology</i> , 2010, 56, 264-271.	2.8	66
115	Outcomes in Diabetic and Nondiabetic Patients Treated With Everolimus- or Paclitaxel-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2010, 56, 2084-2089.	2.8	85
116	Effect of an Olmesartan Medoxomil-Based Treatment Algorithm on Systolic Blood Pressure in Patients with Stage 1 or 2 Hypertension. <i>American Journal of Cardiovascular Drugs</i> , 2010, 10, 239-246.	2.2	4
117	Medical and catheter-based therapies for managing stable coronary disease: Lessons from the COURAGE trial. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2009, 11, 45-53.	0.9	2
118	Adjunctive Pharmacotherapy Part II. <i>Journal of Invasive Cardiology</i> , 2009, 21, A6, A9.	0.4	0
119	Specialized Centers and Systems for Heart Attack Care. <i>The American Heart Hospital Journal</i> , 2008, 6, 14-20.	0.2	10
120	Results of an Olmesartan Medoxomil-Based Treatment Regimen in Hypertensive Patients. <i>Journal of Clinical Hypertension</i> , 2008, 10, 911-921.	2.0	25
121	A Novel Bioresorbable Polymer Paclitaxel-Eluting Stent for the Treatment of Single and Multivessel Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2008, 51, 1543-1552.	2.8	109
122	The Truth and Consequences of the COURAGE Trial. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1598-1603.	2.8	101
123	Enoxaparin vs Unfractionated Heparin in High-Risk Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Managed With an Intended Early Invasive Strategy. <i>JAMA - Journal of the American Medical Association</i> , 2004, 292, 45-54.	7.4	702
124	Inflammation as a therapeutic target: a unique role for abciximab. <i>American Heart Journal</i> , 2003, 146, S1-S4.	2.7	19
125	Pharmacoinvasive management of acute coronary syndrome in the setting of percutaneous coronary intervention: evidence-based, site- and spectrum-of-care strategies for optimizing patient outcomes in NSTEMI-ACS. <i>Journal of Invasive Cardiology</i> , 2003, 15, 536-53.	0.4	6
126	Coronary perforation during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade: An algorithm for percutaneous management. <i>Catheterization and Cardiovascular Interventions</i> , 2001, 52, 279-286.	1.7	122

#	ARTICLE	IF	CITATIONS
127	Point-of-Care Measured Platelet Inhibition Correlates With a Reduced Risk of an Adverse Cardiac Event After Percutaneous Coronary Intervention. <i>Circulation</i> , 2001, 103, 2572-2578.	1.6	361
128	Abciximab Readministration. <i>Circulation</i> , 2001, 104, 870-875.	1.6	143
129	Sustained Suppression of Ischemic Complications of Coronary Intervention by Platelet GP IIb/IIIa Blockade With Abciximab. <i>Circulation</i> , 1999, 99, 1951-1958.	1.6	154
130	Planning, Implementation, and Process Monitoring for Prehospital 12-Lead ECG Diagnostic Programs. <i>Prehospital and Disaster Medicine</i> , 1996, 11, 162-171.	1.3	36